Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling

Drug Metabolism and Disposition

Volumn 40, Issue 5, 2012, Pages 892-901

  Meyer, Michaela ^a   Schneckener, Sebastian ^a   Ludewig, Bernd ^a   Kuepfer, Lars ^a   Lippert, Joerg ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 3; PRAVASTATIN; SULFOTRANSFERASE;

ABCC2 GENE; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DRUG METABOLISM; DRUG UPTAKE; EXPRESSED SEQUENCE TAG; GENE EXPRESSION PROFILING; GENETIC DATABASE; HUMAN; IN VIVO STUDY; INTESTINE; KIDNEY; LIVER; MARKER GENE; MICROARRAY ANALYSIS; PERFORMANCE MEASUREMENT SYSTEM; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUALITY CONTROL; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLC22A8 GENE; SLCO1B1 GENE; SULT1A1 GENE; SULT1A2 GENE; SULT1A3 GENE; SULT1B1 GENE; SULT21A1 GENE; SULT21E1 GENE; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; COMPUTER SIMULATION; DATABASES, GENETIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINE, SMALL; KIDNEY; LIVER; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHARMACOKINETICS; PRAVASTATIN; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84859883744     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.043174     Document Type: Article

References (46)

1. Bruyere A, Decleves X, Bouzom F, Ball K, Marques C, Treton X, Pocard M, Valleur P, Bouhnik Y, Panis Y, et al. (2010) Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol Pharm doi:10.1021/mp100015x.
2. Das D, Dhurjati P, and Wangikar P (2008) Prediction of pharmacokinetic behaviour by combining in vivo and in vitro data in physiologically based pharmacokinetic (PBPK) model: parameter estimation and sensitivity analysis. J IISc 88:57-71.
3. Edginton AN, Schmitt W, and Willmann S (2006) Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 45:1013-1034. (Pubitemid 44436004)
4. Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, Gaub T, Goerlitz L, Jaeger J, Loosen R, Ludewig B, et al. (2011) A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol 2
5. Ekins S, Ecker GF, Chiba P, and Swaan PW (2007) Future directions for drug transporter modelling. Xenobiotica 37:1152-1170. (Pubitemid 350035535)
6. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, and Weinstein SH (1991) Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 19:740-748.
7. Fan J, Chen S, Chow EC, and Pang KS (2010) PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr Drug Metab 11:743-761.
8. Gabrielsson J, Green AR, and Van der Graaf PH (2010) Optimising in vivo pharmacology studies-practical PKPD considerations. J Pharmacol Toxicol Methods 61:146-156.
9. Ge X, Yamamoto S, Tsutsumi S, Midorikawa Y, Ihara S, Wang SM, and Aburatani H (2005) Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 86:127-141. (Pubitemid 40917220)
10. Hatanaka T (2000) Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 39:397-412.
11. Hubbell E, Liu WM, and Mei R (2002) Robust estimators for expression analysis. Bioinformatics 18:1585-1592. (Pubitemid 36097723)
12. Keldenich J (2004) Prediction of human clearance (CL) and volume of distribution (VD). Drug Discov Today Technol 1:389-395.
13. Kivistö KT and Niemi M (2007) Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 24:239-247. (Pubitemid 46072183)
14. Maglott D, Ostell J, Pruitt KD, and Tatusova T (2007) Entrez gene: gene-centered information at NCBI. Nucleic Acids Res 35:D26-D31. (Pubitemid 46056164)
15. Moles CG, Mendes P, and Banga JR (2003) Parameter estimation in biochemical pathways: a comparison of global optimization methods. Genome Res 13:2467-2474. (Pubitemid 37428271)
16. Mwinyi J, Johne A, Bauer S, Roots I, and Gerloff T (2004) Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75:415-421. (Pubitemid 38534562)
17. Nakagomi-Hagihara R, Nakai D, and Tokui T (2007) Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica 37:416-426. (Pubitemid 46572887)
18. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, and Nishimura K (2001) Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297:861-867. (Pubitemid 32472480)
19. Nestorov I (2007) Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 3:235-249.
20. Niemi M, Pasanen MK, and Neuvonen PJ (2006) SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 80:356-366. (Pubitemid 44465886)
21. Nishimura M and Naito S (2005) Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20:452-477.
22. Nishimura M and Naito S (2006) Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21:357-374.
23. Nishimura M, Yaguti H, Yoshitsugu H, Naito S, and Satoh T (2003) Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123:369-375. (Pubitemid 41327466)
24. Obach RS (2011) Predicting clearance in humans from in vitro data. Curr Top Med Chem 11:334-339.
25. Parkinson H, Kapushesky M, Shojatalab M, Abeygunawardena N, Coulson R, Farne A, Holloway E, Kolesnykov N, Lilja P, Lukk M, et al. (2007) ArrayExpress-a public database of microarray experiments and gene expression profiles. Nucleic Acids Res 35:D747-D750. (Pubitemid 46056303)
26. Pelkonen O and Turpeinen M (2007) In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations. Xenobiotica 37:1066-1089. (Pubitemid 350035539)
27. Poulin P and Theil FP (2002a) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129-156. (Pubitemid 34074473)
28. Poulin P and Theil FP (2002b) Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91:1358-1370. (Pubitemid 34651198)
29. Rodgers T, Leahy D, and Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1276. (Pubitemid 40904190)
30. Rodgers T and Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257. (Pubitemid 43874439)
31. Serajuddin AT, Ranadive SA, and Mahoney EM (1991) Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci 80:830-834.
32. Shirasaka Y, Sakane T, and Yamashita S (2008) Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci 97:553-565.
33. Singhvi SM, Pan HY, Morrison RA, and Willard DA (1990) Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 29:239-243. (Pubitemid 20131424)
34. Vicini P (2010) Multiscale modeling in drug discovery and development: future opportunities and present challenges. Clin Pharmacol Ther 88:126-129.
35. Vossen M, Sevestre M, Niederalt C, Jang IJ, Willmann S, and Edginton AN (2007) Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor Biol Med Model 4:13.
36. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
37. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Church DM, DiCuccio M, Edgar R, Federhen S, Helmberg W, et al. (2005) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 33:D39-D45. (Pubitemid 40207828)
38. Wheeler DL, Church DM, Federhen S, Lash AE, Madden TL, Pontius JU, Schuler GD, Schriml LM, Sequeira E, Tatusova TA, et al. (2003) Database resources of the National Center for Biotechnology. Nucleic Acids Res 31:28-33. (Pubitemid 36150327)
39. Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, and Schmitt W (2007) Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34:401-431. (Pubitemid 46873033)
40. Willmann S, Lippert J, and Schmitt W (2005) From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 1:159-168.
41. Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, and Schmitt W (2003) PK-Sim©: a physiologically based pharmacokinetic 'whole-body' model. Biosilico 1:121-124. (Pubitemid 40416764)
42. Willmann S, Schmitt W, Keldenich J, Lippert J, and Dressman JB (2004) A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 47:4022-4031. (Pubitemid 38970963)
43. Willmann S, Thelen K, Becker C, Dressman JB, and Lippert J (2010) Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. Eur J Pharm Biopharm 76:83-94.
44. Wilson CL and Miller CJ (2005) Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis. Bioinformatics 21:3683-3685. (Pubitemid 41264111)
45. Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, and Sugiyama Y (1997) Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos 25:1123-1129. (Pubitemid 27446581)
46. Zuegge J, Schneider G, Coassolo P, and Lavé T (2001) Prediction of hepatic metabolic clearance: comparison and assessment of prediction models. Clin Pharmacokinet 40:553-563. (Pubitemid 32738661)